Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients | Zendy

Seok Lee | Zendy; In Hee Kim | Zendy; SeongHun Kim | Zendy; Sang Wook Kim | Zendy; Seung Ok Lee | Zendy; Soo Teik Lee | Zendy; Dae Ghon Kim | Zendy; Chang Seop Lee | Zendy; Chang Soo Choi | Zendy; Eun Young Cho | Zendy; Haak Cheoul Kim | Zendy

Open Access

Efficacy and Tolerability of Pegylated Interferon-α<sub>2a</sub> plus Ribavirin versus Pegylated Interferon-α<sub>2b</sub> plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

Author(s) -

Seok Lee,

In Hee Kim,

SeongHun Kim,

Sang Wook Kim,

Seung Ok Lee,

Soo Teik Lee,

Dae Ghon Kim,

Chang Seop Lee,

Chang Soo Choi,

Eun Young Cho,

Haak Cheoul Kim

Publication year - 2010

Publication title -

intervirology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.641

H-Index - 61

eISSN - 1423-0100

pISSN - 0300-5526

DOI - 10.1159/000274975

Subject(s) - ribavirin , pegylated interferon , medicine , genotype , gastroenterology , tolerability , interferon , hepatitis c virus , immunology , biology , virus , adverse effect , gene , biochemistry

The authors compared the efficacies and tolerabilities of pegylated interferon-alpha2a (PEG-IFN-alpha2a) + ribavirin and pegylated interferon-alpha2b (PEG-IFN-alpha2b) + ribavirin for the initial treatment of chronic hepatitis C.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research